tyr992

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

Gefitinib (T1181) is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib-D8 is a deuterium labeled Gefitinib.

Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.

[pTyr5] EGFR (988-993) TFA, derived from the Tyr992 autophosphorylation site of the epidermal growth factor receptor (EGFR 988-993), often complexes with catalytically inactive protein-tyrosine phosphate 1B (PTP1B) [1].

Gefitinib-D6 is a deuterated compound of Gefitinib. Gefitinib (T1181) has a CAS number of 184475-35-2. Gefitinib (T1181) is an EGFR tyrosine kinase inhibitor and can inhibit Tyr1173, Tyr992, Tyr1173 and Tyr992 (IC50s: 37/37/26/57 nM).

[pTyr5] EGFR (988-993) is a compound derived from the auto-phosphorylation site Tyr992 in the epidermal growth factor receptor (EGFR 988-993), and it is often associated with the catalytically inactive protein-tyrosine phosphatase 1B (PTP1B).

EGF Receptor Substrate 2 (Phospho-Tyr5) is a biologically active peptide derived from an autophosphorylation site (Tyr992) of EGFR.